Habibizad Nazila

See RemarksGlobal Blood Therapeutics, Inc. (GBT) · full profile →Form 4 · filed Oct 6, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
17
1 non-derivative · 16 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 5, 2022Disposed to issuer(D)40K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 5, 2022Disposed to issuer(D)9380
Oct 5, 2022Disposed to issuer(D)8K0
Oct 5, 2022Disposed to issuer(D)23K0
Oct 5, 2022Disposed to issuer(D)2K0
Oct 5, 2022Disposed to issuer(D)4K0
Oct 5, 2022Disposed to issuer(D)8K0
Oct 5, 2022Disposed to issuer(D)4K0
Oct 5, 2022Disposed to issuer(D)6K0
Oct 5, 2022Disposed to issuer(D)6K0
Oct 5, 2022Disposed to issuer(D)6K0
Oct 5, 2022Disposed to issuer(D)26K0
Oct 5, 2022Disposed to issuer(D)15K0
Oct 5, 2022Disposed to issuer(D)3K0
Oct 5, 2022Disposed to issuer(D)2K0
Oct 5, 2022Disposed to issuer(D)5480
Oct 5, 2022Disposed to issuer(D)29K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-033147) within minutes of acceptance. Every field above traces to the original document. Verify it directly: